{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T13:10:22Z","timestamp":1715346622580},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1097\/ftd.0b013e318286ec33","type":"journal-article","created":{"date-parts":[[2013,5,10]],"date-time":"2013-05-10T10:41:41Z","timestamp":1368182501000},"page":"367-373","source":"Crossref","is-referenced-by-count":4,"title":["Contributing Factors to the Apparent Clearance of Bepridil in Patients With Paroxysmal or Persistent Atrial Fibrillation"],"prefix":"10.1097","volume":"35","author":[{"given":"Tsuyoshi","family":"Shiga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Hashiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyoko","family":"Naganuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhisa","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-14-20210129","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/archinte.1995.00430050045005","article-title":". Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.","volume":"155","author":"Feinberg","year":"1995","journal-title":"Arch Intern Med"},{"key":"R2-14-20210129","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":". Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"R3-14-20210129","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":". Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"R4-14-20210129","doi-asserted-by":"crossref","first-page":"11D","DOI":"10.1016\/0002-9149(92)90953-V","article-title":". Pharmacology of bepridil.","volume":"69","author":"Gill","year":"1992","journal-title":"Am J Cardiol"},{"key":"R5-14-20210129","doi-asserted-by":"crossref","first-page":"63D","DOI":"10.1016\/0002-9149(92)90961-W","article-title":"Effects of bepridil on cardiac electrophysiologic properties.","volume":"69","author":"Prystowsky","year":"1992","journal-title":"Am J Cardiol"},{"key":"R6-14-20210129","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1253\/circj.71.1250","article-title":". Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs.","volume":"71","author":"Miyaji","year":"2007","journal-title":"Circ J"},{"key":"R7-14-20210129","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0002-9149(03)00672-6","article-title":". Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm.","volume":"92","author":"Fujiki","year":"2003","journal-title":"Am J Cardiol"},{"key":"R8-14-20210129","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1253\/circj.69.44","article-title":". Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation.","volume":"69","author":"Nakazato","year":"2005","journal-title":"Circ J"},{"key":"R9-14-20210129","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1253\/circj.CJ-08-1061","article-title":". Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms. A multicenter, randomized, placebo-controlled, double-blind study (J-BAF Study).","volume":"73","author":"Yamashita","year":"2009","journal-title":"Circ J"},{"key":"R10-14-20210129","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1253\/circj.70.662","article-title":". Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter.","volume":"70","author":"Yasuda","year":"2006","journal-title":"Circ J"},{"key":"R11-14-20210129","doi-asserted-by":"crossref","first-page":"8C","DOI":"10.1016\/0002-9149(85)90799-4","article-title":"Pharmacokinetics and metabolism of bepridil.","volume":"55","author":"Benet","year":"1985","journal-title":"Am J Cardiol"},{"key":"R12-14-20210129","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2165\/00003495-199244050-00009","article-title":"Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris.","volume":"44","author":"Hollingshead","year":"1992","journal-title":"Drugs"},{"key":"R13-14-20210129","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1253\/circj.CJ-10-1084","article-title":". Clinical outcome in paroxysmal or persistent atrial fibrillation patients receiving bepridil.","volume":"75","author":"Shiga","year":"2011","journal-title":"Circ J"},{"key":"R14-14-20210129","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2125.1991.tb03971.x","article-title":"Population pharmacokinetics: theory and practice.","volume":"32","author":"Aarons","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"R15-14-20210129","first-page":"501","article-title":"Commentary: what are narrow therapeutic index drugs Clin Pharmacol Ther.","volume":"63","author":"Levy","year":"1998","journal-title":""},{"key":"R16-14-20210129","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-199937010-00003","article-title":". Population pharmacokinetics. A regulatory perspective.","volume":"37","author":"Sun","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"R17-14-20210129","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0378-4347(84)80012-2","article-title":"Determination of bepridil in biological fluids by high-performance liquid chromatography.","volume":"309","author":"Ng","year":"1984","journal-title":"J Chromatogr"},{"key":"R18-14-20210129","first-page":"139","article-title":"Determination of bepridil in human serum using high-performance liquid chromatography in Japanese.","volume":"14","author":"Yamazaki","year":"1998","journal-title":"Rinsho Iyaku"},{"key":"R20-14-20210129","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","article-title":"Diagnosing model diagnostics.","volume":"82","author":"Karlsson","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R21-14-20210129","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","article-title":"Important of shrinkage in empirical Bayes estimation for diagnostics: problem and solutions.","volume":"11","author":"Savic","year":"2009","journal-title":"AAPS J"},{"key":"R22-14-20210129","first-page":"752","article-title":". Bepridil in the elderly. A pharmacokinetic and clinical monitoring study.","volume":"44","author":"Hakamaki","year":"1988","journal-title":"Curr Ther Res Clin Exp"},{"key":"R23-14-20210129","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1248\/bpb.29.517","article-title":". Nonlinear mixed effects model analysis of pharmacokinetics of routinely administered bepridil in Japanese patients with arrhythmias.","volume":"29","author":"Taguchi","year":"2006","journal-title":"Biol Pharm Bull"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e318286ec33","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T12:57:01Z","timestamp":1715345821000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201306000-00014"}},"subtitle":["Analysis Using Population Pharmacokinetics"],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e318286ec33","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}